WaveMan
WaveMan · Company
PMN · Promis Neurosciences Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

PMN ProMIS Neurosciences (PMN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001374339
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter

What the filings say about PMN

Insiders, 180 days
+$30.3K net bought
1 buyer

ProMIS Neurosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ProMIS Neurosciences Inc. insiders bought a net $30.3K of stock across 32 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kaplan Johanne
Chief Development Officer
BUY
2026-08-07 SECtraded 2026-08-05
2,280
$30.3K
-45.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 19, 2026.
  • The trade is 36.7% of the 6,221 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Development Officer Kaplan Johanne bought about $30.3K of PMN on Aug 5, 2026; 10 funds added in the latest 13F quarter.
Kirwin Patrick D.
Director
BUY
2026-04-23 SECtraded 2026-04-22
4,000
$45.3K
-28.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Aug 14, 2024.
  • +0.2% median (-2.7% mean) 90-day return after 5 previous buys.
  • The trade is 86.0% of the 4,653 shares held after it.
  • No other insider bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Kirwin Patrick D. bought about $45.3K of PMN on Apr 22, 2026; 10 funds added in the latest 13F quarter.
Williams Eugene
Director
BUY
2026-03-06 SECtraded 2026-03-05
2,000
$48.8K
-66.1%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Mar 4, 2026.
  • -23.5% median (-29.8% mean) 90-day return after 8 previous buys.
  • The trade is 16.1% of the 12,397 shares held after it.
  • 2 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Eugene bought about $48.8K of PMN on Mar 5, 2026; 2 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Williams Eugene
Director
BUY
2026-03-04 SEC
2,000
$48.0K
-67.5%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Mar 3, 2026.
  • -21.4% median (-25.8% mean) 90-day return after 7 previous buys.
  • The trade is 19.2% of the 10,397 shares held after it.
  • 2 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Eugene bought about $48.0K of PMN on Mar 4, 2026; 2 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
Williams Eugene
Director
BUY
2026-03-04 SECtraded 2026-03-03
1,000
$21.9K
-67.5%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Mar 2, 2026.
  • -17.1% median (-20.5% mean) 90-day return after 6 previous buys.
  • The trade is 11.9% of the 8,397 shares held after it.
  • 2 other insiders bought within 30 days.
  • 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Williams Eugene bought about $21.9K of PMN on Mar 3, 2026; 2 other insiders bought within 30 days and 10 funds added in the latest 13F quarter.
32 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 27 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$30.3K over 180 days
+$30.3K over 90 days
more than 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 82% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.6% of the float short (float per yahoo 2026-10-27) · 7.1 days to cover · settled 2026-10-15
below 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PMN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-25.0%12M
-37%+19%+75%+131%2025-102025-122026-022026-042026-062026-082026-10 2026-02-03 · Yu Fan bought $8.5M2026-03-05 · Williams Eugene bought $48.8K2026-03-04 · Williams Eugene bought $48.0K2026-04-22 · Kirwin Patrick D. bought $45.3K2026-08-05 · Kaplan Johanne bought $30.3K2026-02-19 · Kaplan Johanne bought $25.0K2026-03-02 · Williams Eugene bought $22.5K2026-03-03 · Williams Eugene bought $21.9K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PMN: institutional holders (13F)

13F holdings, latest reported quarter
Jupiter Topco LLC
1,292,757 sh
$17.0M
Deep Track Capital, LP
835,655 sh
$11.0M
WELLINGTON MANAGEMENT GROUP LLP
696,378 sh
$9.2M
Ally Bridge Group (NY) LLC
620,319 sh
$8.2M
Trails Edge Capital Partners, LP
557,103 sh
$7.3M

Congress trades in PMN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PMN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PMN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Nasdaq Composite Index Fund
$61.4K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $30.3K bought by insiders over 180 days, 10 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PMN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$42.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2023-12-31 (30 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-172.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-127.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-176.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$18.9M
market value at close 2026-10-26 on 2026-08-13 shares, plus long-term debt only, 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
FCF yield
-58.3%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$40.2M-$16.8M-$14.3M-$23.4M
Net income-$39.7M$2.8M-$13.2M-$18.1M
EPS (diluted)-22.612.63-1.07-2.41
Operating cash flow-$28.1M-$27.2M-$10.8M-$17.0M
Cash$6.1M$13.3M$12.6M$5.9M
Long-term debtn/an/a$0n/a
SEC XBRL, fiscal years, as known on 2026-10-28

PMN Stock Sonar score 5/7 axes

Find similar shapesCompare

PMN ranks highest on financial health (99th percentile) and insider conviction (63rd), and lowest on profitability (17th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
17
Inputs
  • Return on equity-172.3% · 20 pct, sector of 545
  • Return on assets-127.6% · 18 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-176.7% · 13 pct, sector of 576
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Insider conviction
63
Inputs
  • Net Form 4 buying (codes P and S), 180d$30K · 70 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
18
Inputs
  • Funds adding, latest quarter10 · 18 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
55
Inputs
  • Short interest, % of float+5.6% · 55 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

PMN filings, in plain words

Are ProMIS Neurosciences insiders buying or selling PMN?

In the 180 days to 2026-10-28, ProMIS Neurosciences insiders were net buyers, a net $30.3K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, ProMIS Neurosciences insiders were net buyers of PMN, a net $30.3K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies